Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6


Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors.

Tähtinen S, Kaikkonen S, Merisalo-Soikkeli M, Grönberg-Vähä-Koskela S, Kanerva A, Parviainen S, Vähä-Koskela M, Hemminki A.

PLoS One. 2015 Jun 24;10(6):e0131242. doi: 10.1371/journal.pone.0131242. eCollection 2015.


Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor.

Tähtinen S, Grönberg-Vähä-Koskela S, Lumen D, Merisalo-Soikkeli M, Siurala M, Airaksinen AJ, Vähä-Koskela M, Hemminki A.

Cancer Immunol Res. 2015 Aug;3(8):915-25. doi: 10.1158/2326-6066.CIR-14-0220-T. Epub 2015 May 14.


Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy.

Liikanen I, Koski A, Merisalo-Soikkeli M, Hemminki O, Oksanen M, Kairemo K, Joensuu T, Kanerva A, Hemminki A.

Oncoimmunology. 2015 Apr 2;4(3):e989771. eCollection 2015 Mar.


Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy.

Vähä-Koskela M, Tähtinen S, Grönberg-Vähä-Koskela S, Taipale K, Saha D, Merisalo-Soikkeli M, Ahonen M, Rouvinen-Lagerström N, Hirvinen M, Veckman V, Matikainen S, Zhao F, Pakarinen P, Salo J, Kanerva A, Cerullo V, Hemminki A.

Mol Ther Oncolytics. 2015 Jan 7;1:14006. doi: 10.1038/mto.2014.6. eCollection 2015.


Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans.

Bramante S, Koski A, Kipar A, Diaconu I, Liikanen I, Hemminki O, Vassilev L, Parviainen S, Cerullo V, Pesonen SK, Oksanen M, Heiskanen R, Rouvinen-Lagerström N, Merisalo-Soikkeli M, Hakonen T, Joensuu T, Kanerva A, Pesonen S, Hemminki A.

Int J Cancer. 2014 Aug 1;135(3):720-30. doi: 10.1002/ijc.28696. Epub 2014 Jan 10.


Oncolytic virotherapy trials--letter.

Hemminki A, Oksanen M, Merisalo-Soikkeli M.

Clin Cancer Res. 2013 Aug 15;19(16):4541-2. doi: 10.1158/1078-0432.CCR-13-1471. No abstract available.

Supplemental Content

Loading ...
Support Center